Founders Everywhere: Andrew McCarthy
Andrew McCarthy is the co-founder & CEO of Axo Longevity, a preventive health & performance platform that uses biomarker testing to create personalized blueprints for longer, healthier lives.
Welcome to Founders Everywhere, where we highlight the incredible people behind the companies we’ve backed at Everywhere Ventures, a global pre-seed fund supported by a community of 500 founders and operators.
Axo Longevity is a membership-based platform for preventive health, operating in the UK, Spain, the Netherlands, and Germany, and exploring early operations for future Latin American expansion. For around €499 a year (<€42/month) members receive two comprehensive blood panels annually, covering 100+ biomarkers. That goes far beyond the 10–12 markers of a standard medical test. Axo translates these results into clear explanations, personalized insights, and actionable recommendations, additionally members get access to discounted and trusted advanced tests like gut, brain, VO₂, DEXA, biological age, and genetics through curated partners. The platform is building an AI “copilot doctor” that continuously learns from members’ data, making Axo a trusted hub for understanding and optimizing long-term health.
CEO Andrew McCarthy is a serial entrepreneur who teamed up with Sergio Tang-Sanchez and Octavia Seymour. Sergio leads product strategy and go-to-market, while Octavia oversees operations and expansion. Axo’s clinical edge comes from Dr. Niko Mihic, head doctor at Real Madrid and advisor to some of the world’s most elite athletes and organizations, and Dr. Andy Walshe, former director of high performance at Red Bull, who has worked with Olympic athletes, special forces, and major tech companies. The team combines elite performance science, data-driven medicine, and user-friendly product design to guide Axo’s approach to preventive health.
Why Axo Longevity and why now?
I started Axo Longevity after watching a huge mindset shift in consumer health. For years, people assumed, “If I get cancer, heart disease, or Alzheimer’s, my doctor and the healthcare system will save me.” That reactive model is incredibly costly, often traumatic, and increasingly inadequate, as serious diseases show up earlier and more frequently. The real question is not if but when.
At the same time you see the rise of gyms, supplements, biohacking, saunas, cold exposure, and wearables, all converging into what I call the longevity movement. It’s important to understand your body early and act before disease starts. The US has been ahead on this curve; Europe and other regions are about 12 months behind, but demand is building. Public healthcare in Europe is often described as “free,” but in reality it’s limited and reactive. Axo exists to give people a clear, proactive path into preventive health.
What’s Axo Longevity’s North Star?
To increase healthspan - the number of years people live in good health - and bring optimal health to as many people as possible. We’re starting with a wedge of high performers and early adopters, but the goal is very simple and very ambitious: make high-quality preventive health accessible well beyond the 1% and eventually bring it to everyone.
What sets Axo Longevity apart?
We have an outstanding team and unlike traditional healthcare or most consumer health platforms, Axo goes beyond generic “normal” ranges, using 100+ biomarkers. Many of the markers we track (like apolipoproteins and advanced inflammatory markers) are early indicators of cardiovascular disease, metabolic dysfunction, or cancer risk, and yet many clinicians don’t routinely use or even know them. Axo gives you the kind of data and optimization focus that elite athletes and high-performance organizations have had for years.
Tell us about some recent milestones that Axo Longevity crushed.
A particularly meaningful milestone was securing Dr. Niko Mihic and Dr. Andy Walshe’s full commitment. That level of engagement from leaders at the pinnacle of sports medicine adds both credibility and vision to what we’re building.
In addition:
We’ve moved faster than anyone else in our category in Europe.
We signed and integrated labs across markets in roughly eight weeks, where other companies took over a year.
We’ve built a network of around 250 blood-draw locations through lab partners.
Completed a private beta with paying customers and ambassadors
We’ve attracted a waitlist of about 10,000 people
Why the name Axo Longevity?
“Axo” comes from axolotl, a Mexican salamander with remarkable regenerative abilities: it can regrow limbs and repair its own body in ways that almost seem magical. It was nearly extinct before being preserved. The name is a nod to my Mexican roots and a metaphor for regeneration, resilience, and extending healthy life. “Longevity” clarifies what we do. Together they capture our aim to help people repair, optimize, and extend their healthspan.
Fun Fact:
A defining moment for me was climbing Mount Kilimanjaro. I went thinking I’d probably fail and ended up leading the group to the summit every day. That experience rewired my mindset around growth, fear, and potential. It reinforced that we are often capable of much more than we believe, and that’s exactly the philosophy we bring to Axo: your health can be radically better if you’re willing to see the data and act on it.
Listen to Kat Garcia, with Scott Hartley on the Venture Everywhere podcast: Ground Rules. Now on Apple & Spotify. Check out to all our past episodes here!
